Analyst: Darzalex sales could reach top end of projections

Janssen’s recently published sales figures for cancer drug Darzalex indicate a promising year-end result is in store, according to a Sydbank analyst.
Photo: PR / Genmab
Photo: PR / Genmab
by marketwire, translated by daniel pedersen

On Tuesday, Genmab saw a bad stock market start turn around after its partner, US-based pharmaceutical firm Johnson & Johnson, released its first quarter figures for 2022, which revealed a sales advancement for bone marrow cancer drug Darzalex.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading